As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for samples received on April 20, at the Charlotte, Dallas, Phoenix, St. Louis and Tampa laboratories. Babesia is a selective pooled NAT test, required for all blood donations collected by May 2020, in 14 States and the District of Columbia. To help you understand the requirements, CTS will host a Babesia Implementation and Review webinar on March 3, 2020 at 11:00 am CST. If you are interested in attending, please contact your Customer Service Manager for invitation details.
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...